The demographic data and characteristics of AMSAN (1 case) and AMAN (1 case).
| Characteristic | Case 1 | Case 2 |
|---|---|---|
| Author (yr) | Farah R(2005) | Kraus J(2007) |
| Population | Israel | Caucasian |
| Gender | M | M |
| Age | 71(AMSAN) | 65(AMAN) |
| Preceding factors | + | + |
| Clinical characteristics | Limb weakness, areflexia, ptosis, dysarthria, dysphagia, respiratory failure | Limb weakness, areflexia, ptosis, dysarthria, dysphagia, respiratory failure |
| Albumino-cytologic dissociation | + | + |
| Nerve conduction | + | + |
| RNS | - | + |
| Anti-AChR antibody | - | + |
| Anti-GQ1b antibody | - | + |
| Edrophonium chloride | - | + |
| Treatment | plasmapheresis, IVIG | IVIG, corticosteroids, pyridostigmine, azathioprine |
| Thymectomy | - | - |
| Prognosis | 6 | 2 |
M- Male, F - Female, yr - Year, MG - Myasthenia gravis, AMAN - acute motor axonal neuropathy, AMSAN - acute motor-sensory axonal neuropathy, IVIG - intravenous immunoglobulin, RNS - repetitive nerve stimulation. Functional outcome was ranked according to the adopted scale by Hughes: 0, healthy; 1, minor symptoms or signs, able to run; 2, able to walk >5 m without assistance, but unable to run; 3, able to walk >5 m with assistance; 4, bed- or chair-bound; 5, requiring assisted ventilation for at least part of the day; and 6, dead. “+” indicates the patient had precipitating factors from infectious disease.”-” indicates the patient did not have precipitating factors from infectious disease. As for the other parameters, “+” indicates positive findings, and “-” indicates negative findings